Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain: A Prospective, Randomized, Controlled, Multi-center, Phase III Trial

NCT04533243 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT04533243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04533243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain: A Prospective, Randomized, Controlled, Multi-center, Phase III Trial
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2020
Completion date
August 31, 2022
Enrollment
209 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

opioid, moderate cancer pain, transdermal fentanyl, 12.5ug/h, opioid-naive